Lucia Grumetto | Predictive Analytics | Best Researcher Award

Posted on by ScienceFather

Prof. Lucia Grumetto | Predictive Analytics | Best Researcher Award

Università di napoli Dipartimento di Farmacia, Italy

👨‍🎓 Author Profiles

🎓 Academic Foundations and Professional Development

Prof. Lucia Grumetto’s academic path began at the University of Naples Federico II, where she completed dual degrees in Pharmacy and Biological Sciences. Over her extensive career, she gained considerable experience as a Researcher, later advancing to Associate Professor in the same institution. Her qualifications are further reinforced by a Master’s Degree in Food Law (2014), underscoring her ability to integrate scientific knowledge with legal and regulatory expertise, particularly in food safety.

💼 Professional Endeavors and Expertise

Throughout her career, Prof. Grumetto has contributed significantly to both pharmaceutical research and education. Her professional journey spans multiple roles, including Researcher, Professor, and Consultant in the areas of toxicology, pharmacokinetics, and environmental health. She has been actively involved in key research initiatives aimed at understanding the behavior of endocrine disruptors in biological systems, including the human blood-brain barrier and ocular barriers. Her research projects on sustainable drug formulations and environmental monitoring are crucial in addressing both public health and ecological concerns.

🔬 Research Focus and Scientific Contributions

Prof. Grumetto’s research has a broad scope, ranging from drug development to environmental health. She has led investigations into the pharmacokinetics of pharmaceutical compounds, focusing on their absorption, distribution, and metabolism in different biological systems. Her work on the interaction of endocrine disruptors in food and environmental matrices has positioned her as a leading expert in toxicology. Notable projects include the study of pharmaceutical permeation through biological membranes and the development of novel drug delivery systems targeting cancer therapies. Her contributions have been widely recognized through numerous publications, awards, and collaborations with international research networks.

🌍 Impact on Academia and Scientific Communities

Prof. Grumetto has profoundly impacted the scientific community through her research, teaching, and publications. With over 80 peer-reviewed papers and presentations at global conferences, she has shared her expertise in pharmacokinetics, endocrine toxicology, and drug testing. Her work on endocrine disruptors has not only influenced academic research but also shaped policies on environmental safety and public health. Her Most Cited Paper Award from the European Journal of Pharmaceutical Sciences and the Best Poster Award at various symposia are testaments to her influence. Additionally, she serves on the Editorial Boards of several high-impact journals, further contributing to the academic world.

👩‍🏫 Teaching and Pedagogical Innovations

Prof. Grumetto is deeply committed to education, having taught various specialized courses at the University of Naples Federico II. Her courses, such as Quality Control and Food Safety Regulations and Xenobiotic Analysis, are integral parts of the curricula for students pursuing degrees in Nutraceutical Sciences and Pharmaceutical Sciences. Beyond her classroom responsibilities, she has taken on leadership roles in shaping internship programs and curricular development, ensuring students gain hands-on experience and the necessary skills to succeed in their professional careers.

🔧 Technical Expertise and Analytical Innovations

One of Prof. Grumetto’s strengths lies in her technical expertise, particularly in the field of analytical chemistry. Her pioneering work with HPLC, mass spectrometry, and immobilized artificial membranes (IAM) has significantly advanced pharmacokinetic research. She has developed innovative methodologies for studying drug interactions and their bioavailability, especially for substances that cross biological barriers like the blood-brain barrier. These techniques are essential for understanding drug absorption and improving drug delivery systems.

🏆 Recognition, Awards, and Achievements

Prof. Grumetto’s contributions have been recognized with numerous awards and honors. In addition to her Best Poster Awards at international conferences, she received the Most Cited Paper Award from the European Journal of Pharmaceutical Sciences. She holds several patents, including one for a dermatological patch test device to identify allergic reactions to medications. Her innovations have extended beyond the academic realm, influencing practical applications in medicine, environmental monitoring, and sustainability.

🚀 Future Contributions and Vision

Looking ahead, Prof. Grumetto continues to push boundaries in both pharmaceutical research and sustainability. Her current projects, such as FRUIPAD, aim to create biodegradable food packaging from fruit by-products, highlighting her commitment to both environmental sustainability and public health. Her ongoing studies in endocrine disruptors and drug delivery systems hold the potential to influence future healthcare strategies, particularly in personalized medicine and targeted therapies. As she continues to lead innovative projects and collaborate internationally, her future contributions will likely reshape the way pharmaceuticals and environmental health issues are addressed globally.

📖 Top Noted Publications

 The combined use of biological investigations, bio chromatographic and in silico methods to solve the puzzle of badge and its derivative’s toxicity
  • Authors: Ilaria Neri, Marialuisa Piccolo, Giacomo Russo, Maria Grazia Ferraro, Vincenzo Marotta, Rita Santamaria, Lucia Grumetto
    Journal: Chemosphere
    Year: 2024
Phenylalanine Butyramide: A Butyrate Derivative as a Novel Inhibitor of Tyrosinase
  • Authors: Ritamaria Di Lorenzo, Vincenzo Di Lorenzo, Teresa Di Serio, Adua Marzocchi, Lucia Ricci, Eleonora Vardaro, Giovanni Greco, Maria Maisto, Lucia Grumetto, Vincenzo Piccolo et al.
    Journal: International Journal of Molecular Sciences
    Year: 2024
Investigating the Effect of Surface Hydrophilicity on the Destiny of PLGA-Poloxamer Nanoparticles in an In Vivo Animal Model
  • Authors: Teresa Silvestri, Lucia Grumetto, Ilaria Neri, Maria De Falco, Sossio Fabio Graziano, Sara Damiano, Daniela Giaquinto, Lucianna Maruccio, Paolo de Girolamo, Fabrizio Villapiano et al.
    Journal: International Journal of Molecular Sciences
    Year: 2023
Dermocosmetic evaluation of a nutricosmetic formulation based on Curcuma
  • Authors: Ritamaria Di Lorenzo, Lucia Grumetto, Antonia Sacchi, Sonia Laneri, Irene Dini
    Journal: Phytotherapy Research
    Year: 2023
Validation of an LC-MS/MS Method for the Determination of Abscisic Acid Concentration in a Real-World Setting
  • Authors: Elisabetta Schiano, Ilaria Neri, Maria Maisto, Ettore Novellino, Fortuna Iannuzzo, Vincenzo Piccolo, Vincenzo Summa, Lucia Grumetto, Gian Carlo Tenore
    Journal: Foods
    Year: 2023

Vicenta Llorente Cortés | Social Impact | Best Researcher Award

Posted on by ScienceFather

Dr. Vicenta Llorente Cortés | Social Impact | Best Researcher Award

Consejo Superior Investigaciones Cientificas, Spain

👨‍🎓Professional Profile

Scopus Profile

👩‍🔬 Early Academic Pursuits

Dr. Vicenta Llorente Cortés’s academic journey began with a Bachelor’s degree in Biology from Universitat Autònoma de Barcelona in 1989. She pursued advanced studies in Biochemistry, Molecular Biology, and Biomedicine, completing her degree in 1995. These early academic experiences laid the foundation for her future research career in the fields of cardiovascular science and pathology.

📚 Professional Endeavors and Research Focus

Dr. Llorente Cortés’s professional career has been deeply rooted in scientific research, particularly in the areas of cardiovascular diseases, metabolic disorders, and cellular pathophysiology. She has been a Scientist at the Consejo Superior de Investigaciones Científicas (CSIC) since 2006. Throughout her career, she has held senior research positions, including at the Hospital de Sant Pau and Fundación Investigación Cardiovascular. Her work in experimental pathology at CSIC focuses on understanding the molecular mechanisms of heart failure, cholesterol metabolism, and related diseases.

🧬 Contributions and Research Achievements

Dr. Llorente Cortés has made significant contributions to both basic and applied research, particularly in the field of cardiovascular and metabolic diseases. She has directed 14 doctoral theses, 6 final degree projects, and 10 final Master’s projects, illustrating her commitment to fostering the next generation of researchers. Her scientific output includes 120 international publications, with 36 (51.4%) ranking in the top 25% of the most cited worldwide. Dr. Llorente Cortés’s work has been pivotal in advancing the understanding of cardiovascular pathophysiology and identifying new therapeutic targets, such as vascular cholesterol inhibitors and biomarkers for dilated cardiomyopathy.

🌍 Impact and Influence in the Scientific Community

Dr. Llorente Cortés’s impact extends beyond her own research. She is an active evaluator for scientific projects in Spain, collaborating with organizations like the ANEP, the Junta de Andalucía, and the Spanish Society of Cardiology. Her international collaborations span countries like France, Italy, and the USA, with 30% of her publications being co-authored with foreign researchers. As a reviewer for prestigious journals and a member of several scientific committees, she continues to shape the direction of cardiovascular research globally. Furthermore, her leadership in competitive projects and participation in high-profile international symposiums underscores her influence.

📊 Academic Citations and Recognition

Dr. Llorente Cortés’s academic excellence is reflected in her high citation index. She has an H-index of 34, with a total of 3,150 citations, of which 2,195 are not her own. This high citation count and her consistent publication in top-tier journals (66.2% of her publications appear in the top 25% by cite score) highlight her substantial contribution to the field. Her leadership and expertise are recognized worldwide, as evidenced by her membership in various international scientific societies and networks.

🧪 Technical Skills and Expertise

Dr. Llorente Cortés possesses extensive technical expertise in molecular biology, cardiovascular research, and experimental pathology. Her skill set includes advanced techniques in cellular biology, molecular diagnostics, and the development of therapeutic strategies. She has been instrumental in translating scientific research into potential clinical applications, as demonstrated by her patents and collaborations with companies like Iproteos S.L.

🎓 Teaching Experience and Mentorship

Dr. Llorente Cortés has been an influential mentor throughout her career. In addition to guiding doctoral and postdoctoral researchers, she has contributed to numerous academic projects, fostering a productive environment for new scientists to thrive. She has directed numerous doctoral theses, and her ability to inspire and lead has made her a prominent figure in the academic community.

🔮 Legacy and Future Contributions

Dr. Llorente Cortés’s legacy is defined not only by her groundbreaking research but also by her significant role in mentoring the next generation of scientists and promoting international collaboration. Her future contributions are poised to focus on translational research, particularly in the areas of heart failure therapies and the development of novel diagnostic and therapeutic strategies for cardiovascular diseases. With the continued success of her research projects, including her involvement in innovative programs like InnoPau and CIBERINNOVA, Dr. Llorente Cortés will likely remain a key figure in the global scientific community, advancing both fundamental knowledge and clinical applications.

 

📖Top Noted Publications

PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia

Authors: Borràs, C., Canyelles, M., Girona, J., Blanco-Vaca, F., Escolà-Gil, J.C.

Journal: JACC: Basic to Translational Science

Year: 2024

Targeting LDL Aggregation Decreases Atherosclerotic Lipid Burden in a Humanized Mouse Model of Familial Hypercholesterolemia: Crucial Role of ApoB100 Conformational Stabilization

Authors: Benitez-Amaro, A., Garcia, E., La Chica Lhoëst, M.T., Escola-Gil, J.C., Llorente-Cortés, V.

Journal: Atherosclerosis

Year: 2024

sICAM-1 Concentrations Are Associated with Inflammation in Contralateral Carotid Plaque in Patients with Ischemic Stroke

Authors: Puig, N., Camps-Renom, P., Garcia, E., Llorente-Cortés, V., Benitez, S.

Journal: Clínica e Investigación en Arteriosclerosis

Year: 2024

Mechanisms Modulating Foam Cell Formation in the Arterial Intima: Exploring New Therapeutic Opportunities in Atherosclerosis

Authors: La Chica Lhoëst, M.T., Martinez, A., Claudi, L., Escolà-Gil, J.C., Llorente-Cortés, V.

Journal: Frontiers in Cardiovascular Medicine

Year: 2024

Transcriptional Analysis Reveals that the Intracellular Lipid Accumulation Impairs Gene Expression Profiles Involved in Insulin Response-associated Cardiac Functionality

Authors: Actis Dato, V., Paz, M.C., Rey, F.E., Chiabrando, G.A., Ceschin, D.G.

Journal: Scientific Reports

Year: 2023

farnaz shokraneh | personalized medicine | Best Researcher Award

Posted on by ScienceFather

Ms. farnaz shokraneh | personalized medicine | Best Researcher Award

Abo Akademi University, Finland

👨‍🎓Professional Profile 

Orcid Profile

👩‍🔬 Summary

Ms. Farnaz Shokraneh is an experienced pharmaceutical professional currently working as a Doctoral Researcher in Pharmaceutical Development and Medical Technology at Åbo Akademi University in Turku, Finland. With a solid academic background and extensive practical experience in pharmaceutical quality assurance, regulatory compliance, and research, she brings valuable insights into the development of pharmaceutical products and systems. She is committed to advancing personalized medicine and improving quality control in the pharmaceutical industry.

🎓 Education

Ms. Shokraneh holds a Doctor of Pharmacy degree, equivalent to a Finnish Master’s, from Islamic Azad University, Tehran, Iran (2007-2012). She furthered her academic journey with a Master’s in Pharmaceutical Research from Freie Universität Berlin, Germany (2022-2024). Currently, she is pursuing her doctoral research in Pharmaceutical Development and Medical Technology at Åbo Akademi University, Turku, Finland (2022–present).

💼 Professional Experience

Ms. Shokraneh has accumulated extensive experience in various roles within the pharmaceutical industry. She is currently serving as a Quality Manager at CurifyLabs Oy in Helsinki, Finland, since September 2022. Previously, she held the position of Quality Assurance Manager at Mofid Pharma under the license of Bayer Pharmaceutical Company (Dec 2020–Dec 2021). Additionally, she has worked at Modava Pharmaceutical under Novartis (Jul 2018–Jul 2020) and ATI Pharmed Pharmaceutical Co under StragenPharma and CHEMO Pharmaceutical licenses (Apr 2013–Jun 2017).

🛠️ Technical Skills

Ms. Shokraneh’s technical expertise encompasses pharmaceutical development, quality assurance, and regulatory compliance. She is proficient in analytical techniques such as HPLC, mass spectrometry, and micro NIR spectrophotometry. Her experience also extends to pharmacovigilance, safety monitoring, and statistical analysis for pharmaceutical applications, making her highly skilled in ensuring the safety, efficacy, and quality of pharmaceutical products.

🧑‍🏫 Teaching Experience

Although Ms. Shokraneh’s current focus is on research and industry roles, her vast knowledge and experience in the pharmaceutical field allow her to effectively mentor teams and share her expertise. She has contributed to the professional development of her colleagues and participated in educational training programs within the pharmaceutical sector.

🔬 Research Interests

Ms. Shokraneh’s primary research interests lie in pharmaceutical development and medical technology, with a particular focus on personalized medicine. She is passionate about improving drug safety and efficacy through innovations in automated pharmacy compounding, quality control, and exploring new methods for drug delivery and patient-specific treatment plans.

 

📖Top Noted Publications

Automated Non-Sterile Pharmacy Compounding: A Multi-Site Study in European Hospital and Community Pharmacies with Pediatric Immediate Release Propranolol Hydrochloride Tablets

Authors: Niklas Sandler Topelius, Farnaz Shokraneh, Mahsa Bahman, Julius Lahtinen, Niko Hassinen, Sari Airaksinen, Soumya Verma, Ludmila Hrizanovska, Jana Lass, Urve Paaver et al.

Journal: Pharmaceutics

Year: 2024

A Novel High Performance Liquid Chromatographic Method for Determination of Nystatin in Pharmaceutical Formulations by Box–Behnken Statistical Experiment Design

Authors: Farnaz Shokraneh

Journal: Iranian Journal of Pharmaceutical Research

Year: 2014

Comparative Studies of Cytotoxic Manufacturing Practices in Specialized Cancer Centers Against International Guidelines (ASHP, OSHA, HSE-UK)

Authors: Farnaz Shokraneh

Journal: FIP Congress

Year: 2012

Development and Validation of High-Performance Liquid Chromatography for Determination of Nystatin in Pharmaceutical Formulations

Authors: Farnaz Shokraneh

Journal: Research in Pharmaceutical Science

Year: 2012

A New HPLC Method for Determination of Losartan in Human Plasma and Its Application in Bioequivalence Studies

Authors: Farnaz Shokraneh

Journal: Oriental Journal of Chemistry

Year: 2012

Risks to Health Professionals from Hazardous Drugs in Iran: A Pilot Study of Understanding of Healthcare Team to Occupational Exposure to Cytotoxics

Authors: Farnaz Shokraneh

Journal: EXCLI Journal

Year: 2005

Håkan Jankensgård | Quantitative Social Science Research | Best Researcher Award

Posted on by ScienceFather

Dr. Håkan Jankensgård | Quantitative Social Science Research | Best Researcher Award

Dr. Håkan Jankensgård at Stockholm University, Sweden

Professional Profile👨‍🎓

Early Academic Pursuits 🎓

Dr. Håkan Jankensgård’s academic journey began with a strong foundation at Lund University, Sweden, where he completed both his MSc in Business Administration (2001) and later his PhD in Business Administration (2011). His dissertation, titled “Essays on Corporate Risk Management,” reflects his early academic focus on risk management, which has become the cornerstone of his research career. His education was further enriched by several specialized courses, including Lärarrollen vid universitet och högskola (2014) and The Good Lecture (2015), honing his teaching and supervisory skills.

Professional Endeavors 💼

Dr. Jankensgård’s professional career spans both academia and industry, bringing practical expertise into the classroom. From 2001 to 2003, he served as a Risk Manager at Norsk Hydro in Oslo, Norway, where he gained valuable real-world experience in corporate risk management. His consulting role at Lund, Sweden, from 2004 to 2012, deepened his understanding of corporate finance and risk strategies. This combination of academic excellence and hands-on industry experience makes him a well-rounded academic and consultant.

Contributions and Research Focus 🔍

Dr. Jankensgård’s research is centered on corporate risk management, with an emphasis on understanding how businesses navigate and mitigate financial risks. His work on the role of CEOs in risk management and his long-term study on the effectiveness of corporate risk management have made significant contributions to the field. His research has been supported by prestigious funding bodies like the Jan Wallander and Tom Hedelius Foundations, showcasing his reputation within the academic and professional community. Notably, his studies have questioned the true effectiveness of corporate risk management, offering new insights into the implementation and value of risk strategies in business.

Impact and Influence 🌍

Dr. Jankensgård’s influence extends far beyond his research. He has been actively involved in shaping the discourse on corporate finance, risk, and resilience. He regularly speaks at high-profile events, such as the Svenska Finansanalytikers Förbund and the Rotary Stockholm, and contributes to discussions on risk governance, strategy, and financial forecasting. As a member of various academic and professional committees, including his role on the FFUN committee at Lund University, he has been integral in shaping academic appointments and ensuring the integrity of academic processes.

Academic Citations 📚

Dr. Jankensgård’s research has garnered significant academic attention, with over 820 citations and an H-index of 13 on Google Scholar. His works are widely read, with 5,293 downloads on SSRN, placing him in the top 5% of authors on the platform. These numbers reflect his growing impact in the fields of corporate finance and risk management, as scholars and practitioners continue to engage with his work.

Technical Skills ⚙️

Dr. Jankensgård’s technical expertise is vast, particularly in risk management, corporate finance, and valuation. He has a deep understanding of financial markets, risk governance, and resilience strategies, all of which he integrates into his teaching and research. His ability to apply theoretical knowledge to real-world scenarios, combined with his technical proficiency in financial modeling and corporate strategy, has made him a sought-after consultant and speaker.

Teaching Experience 📚

Dr. Jankensgård’s teaching experience spans over a decade, during which he has developed and led several key courses. As the instructor and course director for courses like Managerial Finance, Corporate Risk Management, and Corporate Valuation at both Lund University and Stockholm University, he has impacted the education of hundreds of students. His courses have been highly ranked, with students consistently praising their relevance to future careers. Beyond course delivery, he is an active doctoral supervisor, guiding 8-15 thesis students annually and contributing to their academic growth.

Legacy and Future Contributions 🚀

Dr. Jankensgård’s legacy lies in his commitment to bridging theory and practice in corporate finance and risk management. As an educator, researcher, and industry expert, he continues to shape the future of the field. His ongoing research projects and speaking engagements suggest that his influence will only grow in the coming years. His contributions to understanding corporate risk, valuation, and resilience will continue to guide future research and industry practices.

YouTube Channel 📹

In addition to his academic work, Dr. Jankensgård has embraced digital media to further educate and engage with a wider audience. His YouTube channel, Jankensgard on Risk, launched in 2021, is dedicated to the theory and practice of risk management. With 250+ subscribers, it serves as an accessible platform for students, professionals, and enthusiasts interested in corporate risk strategies.

Doctoral Supervision 📝

Dr. Jankensgård is deeply involved in the academic development of doctoral students. He has supervised several PhD candidates, including Nick Christie, whose thesis explores financial constraints, risk, and investment. His active participation in doctoral committees, such as the grading of doctoral dissertations, further highlights his commitment to advancing academic knowledge and supporting the next generation of scholars.

 

Top Noted Publications 📖